These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 8221241

  • 1. [The association of Graves' disease with serum soluble interleukin 2 receptor].
    Ren YZ, Song ZG.
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):264-5, 317. PubMed ID: 8221241
    [Abstract] [Full Text] [Related]

  • 2. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
    Balázs C, Farid NR.
    Acta Med Hung; 1991 May; 48(1-2):3-11. PubMed ID: 1813855
    [Abstract] [Full Text] [Related]

  • 3. Serum soluble interleukin 2 receptor in hyperthyroid Graves' disease and effect of carbimazole therapy.
    Chow CC, Lai KN, Leung JC, Chan JC, Cockram CS.
    Clin Endocrinol (Oxf); 1990 Sep; 33(3):317-21. PubMed ID: 2253407
    [Abstract] [Full Text] [Related]

  • 4. Propylthiouracil and carbimazole associated-antineutrophil cytoplasmic antibodies (ANCA) in patients with Graves' disease.
    Harper L, Chin L, Daykin J, Allahabadia A, Heward J, Gough SC, Savage CO, Franklyn JA.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):671-5. PubMed ID: 15163328
    [Abstract] [Full Text] [Related]

  • 5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
    He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW.
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
    [Abstract] [Full Text] [Related]

  • 6. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
    Molnár I.
    Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
    [Abstract] [Full Text] [Related]

  • 7. The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism.
    Tsai WC, Pei D, Wang TF, Wu DA, Li JC, Wei CL, Lee CH, Chen SP, Kuo SW.
    Clin Endocrinol (Oxf); 2005 May; 62(5):521-4. PubMed ID: 15853819
    [Abstract] [Full Text] [Related]

  • 8. Predictor of outcome of hyperthyroidism due to Graves disease: serum triiodothyronine/thyroxine ratio.
    Khanna CM, Shankar LR, Jaggi CB, Bansal JK, Chugh P.
    J Assoc Physicians India; 1996 Feb; 44(2):98-101. PubMed ID: 10999059
    [Abstract] [Full Text] [Related]

  • 9. Influence of thyroxine on serum soluble interleukin-2 receptor alpha levels in thyroid disorders.
    Zwirska-Korczala K, Berdowska A, Jochem J, Sitkiewicz A, Birkner E, Polaniak R, Jedrzejowska-Szypułka H, Korzonek-Szlacheta I.
    J Clin Pharm Ther; 2004 Apr; 29(2):151-6. PubMed ID: 15068404
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
    Koukkou E, Panayiotidis P, Alevizou-Terzaki V, Thalassinos N.
    J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
    [Abstract] [Full Text] [Related]

  • 12. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J, Sugawara M, Kuma K, Kobayashi A, Matsuzuka F, Mozai T, Hershman JM.
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [Abstract] [Full Text] [Related]

  • 13. Serum IL-18 levels are not increased in patients with untreated Graves' ophthalmopathy.
    Wakelkamp IM, Prummel MF, Wiersinga WM.
    Horm Metab Res; 2004 Jan; 36(1):44-7. PubMed ID: 14983406
    [Abstract] [Full Text] [Related]

  • 14. Serum cytokines levels in Graves' disease.
    Al-Humaidi MA.
    Saudi Med J; 2000 Jul; 21(7):639-44. PubMed ID: 11500727
    [Abstract] [Full Text] [Related]

  • 15. [A study of cytokine expression in peripheral blood of patients with Graves' ophthalmopathy].
    Tang L, Luo Q, Zhou X, Xia R.
    Zhonghua Yan Ke Za Zhi; 2002 Mar; 38(3):165-7. PubMed ID: 11955323
    [Abstract] [Full Text] [Related]

  • 16. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T, Holle LH, Schroth HJ, Garth H.
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [Abstract] [Full Text] [Related]

  • 17. Treatment outcome of Graves' disease in Thai children.
    Somnuke PH, Pusuwan P, Likitmaskul S, Santiprabhob J, Sawathiparnich P.
    J Med Assoc Thai; 2007 Sep; 90(9):1815-20. PubMed ID: 17957924
    [Abstract] [Full Text] [Related]

  • 18. Serum Th1 and Th2 profile cytokine level changes in patients with Graves' ophthalmopathy treated with corticosteroids.
    Myśliwiec J, Kretowski A, Topolska J, Siewko K, Jakubczyk D, Szelachowska M, Mikita A, Kinalska I.
    Horm Metab Res; 2001 Dec; 33(12):739-43. PubMed ID: 11753760
    [Abstract] [Full Text] [Related]

  • 19. [Clinical significance of increased serum soluble interleukin-2 receptor levels in patients with pulmonary tuberculosis].
    Chui JJ, Fan P, Li J.
    Zhonghua Jie He He Hu Xi Za Zhi; 1994 Oct; 17(5):288-90, 318-9. PubMed ID: 7712570
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.